Drug
FH 006
FH 006: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| FH-006 NCT07790380 | Phase 3 | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy |
Latest
No recent events.
Follow FH 006 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.